· UCB leads collaboration to design a prefilled pen for patients with rheumatic diseases
· Prefilled Pen designed for ease of use during self-injection
Slough, UK, 25 October 2016: UCB today announces that the new certolizumab pegol (Cimzia®) AutoClicks® Prefilled Pen is now available on the NHS following the recent positive opinion by the European Medicine’s Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The EMA’s CHMP decision recommended the use of Cimzia® AutoClicks® Prefilled Pen in all approved indications (rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis [AS] and axial spondyloarthritis [axSpA]).
UCB is committed to providing value to patients and meeting their unique needs. As part of this commitment, UCB continued its partnership with OXO, a company known for thoughtful, consumer-friendly designs, to develop the AutoClicks® Prefilled Pen, based on core technology licensed from Bespak. The AutoClicks® Prefilled Pen provides a button-free delivery system and a wide non-slip grip that keeps patient hand disability in mind.
Dr Ravik Mascarenhas, Consultant Rheumatologist at the Royal Devon & Exeter Foundation Trust said, “I see many patients whose joints have been destroyed by this painful disease so having a new choice is welcomed. Like most of us they also tend to find it a challenge self-injecting because of a needle – with this new pre-filled pen the patient doesn’t even see the needle which may take some of the nerves and fear away.”Editor's Details
Last updated on: 25/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.